The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; none of the 52 sources its claims cite is checked for support yet.
Identification of the (Pro)renin Receptor as a Novel Regulator of Low-Density Lipoprotein Metabolism
Open accessAbstract
Rationale: The (pro)renin receptor ([P]RR) interacts with (pro)renin at concentrations that are >1000× higher than observed under (patho)physiological conditions. Recent studies have identified renin–angiotensin system–independent functions for (P)RR related to its association with the vacuolar H + -ATPase. Objective: To uncover renin–angiotensin system–independent functions of the (P)RR. Methods and Results: We used a proteomics-based approach to purify and identify (P)RR-interacting proteins. This resulted in identification of sortilin-1 (SORT1) as a high-confidence (P)RR-interacting protein, a finding which was confirmed by coimmunoprecipitation of endogenous (P)RR and SORT1. Functionally, silencing (P)RR expression in hepatocytes decreased SORT1 and low-density lipoprotein (LDL) receptor protein abundance and, as a consequence, resulted in severely attenuated cellular LDL uptake. In contrast to LDL, endocytosis of epidermal growth factor or transferrin remained unaffected by silencing of the (P)RR. Importantly, reduction of LDL receptor and SORT1 protein abundance occurred in the absence of changes in their corresponding transcript level. Consistent with a post-transcriptional event, degradation of the LDL receptor induced by (P)RR silencing could be reversed by lysosomotropic agents, such as bafilomycin A1. Conclusions: Our study identifies a renin–angiotensin system–independent function for the (P)RR in the regulation of LDL metabolism by controlling the levels of SORT1 and LDL receptor.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Using an unbiased proteomics screen, the authors identify the (pro)renin receptor [(P)RR] as a novel post-transcriptional regulator of LDL metabolism through interaction with sortilin 1 (SORT1). (P)RR depletion reduces SORT1 and LDLR protein abundance, lowers cellular LDL uptake, and points to a role in LDLR trafficking rather than gross endocytic failure.
Key findings
- TAP-based proteomics in HEK293 cells identified 40 proteins copurifying with N-terminally TAP-tagged (P)RR in 2 independent purifications; SORT1 had the highest Mascot score and was not found in the CRAPome. Endogenous (P)RR–SORT1 interaction was validated by coimmunoprecipitation, whereas TRAF4 did not coimmunoprecipitate with endogenous (P)RR.
- Silencing (P)RR decreased SORT1 protein abundance by 42% without changing SORT1 transcript levels. It also reduced total LDLR and cell-surface LDLR and decreased LDL uptake: approximately 2-fold in A431 cells, 40% in HepG2 cells, and similarly in Huh7 cells; the effect was minimal in LDLR-deficient LDLA7 CHO cells.
- Combined silencing of (P)RR and SORT1 did not additively reduce LDL uptake compared with either alone, and SORT1 silencing also reduced LDLR abundance and LDL uptake. Lysosomotropic agents bafilomycin A1, NH4Cl, and chloroquine rescued LDLR levels after (P)RR silencing but did not rescue SORT1.
- Transferrin and EGF uptake were not decreased after (P)RR silencing, arguing against a gross defect in clathrin-dependent endocytosis.
Methods
- Cell culture and transfection: HEK293, A431, Huh7, HepG2, and LDLA7 CHO cells were maintained under standard conditions; siRNA and plasmid transfections were performed with Lipofectamine 2000, JetPrime, or RNAiMax, generally after sterol depletion to increase LDLR expression.
- Proteomics and protein analysis: (P)RR interactome was mapped in HEK293 cells using a TAP-based approach with 2 independent purifications and compared with CRAPome; coimmunoprecipitation, immunoblotting, and quantitative PCR were used to validate interactions and expression changes.
- Functional assays and statistics: LDL uptake was measured with DyLight 488-labeled LDL; cell-surface LDLR was measured by FACS; surface-biotinylated LDLR was followed over time; lysosomotropic agents were tested. Data are mean±SEM, with one-way ANOVA plus Bonferroni correction or Student’s t test; P<0.05 was considered significant.
Limitations
- The paper states that siRNA was used to suppress (P)RR, whereas prior studies used Cre-Lox genetic ablation, so minimal (P)RR levels may remain. It also states that the mechanism underlying reduced SORT1 protein after (P)RR silencing remains currently unknown.
- The paper states that future studies are needed to assess the full spectrum of proteins regulated by the (P)RR–SORT1 interaction and to elucidate the role of (P)RR in lipoprotein metabolism in vivo.
- Evident from the text: the findings are based on cultured cell lines, with no in vivo or human data; the proteomic screen used a heterologous N-terminally TAP-tagged (P)RR and many identified proteins were also high-frequency CRAPome contaminants.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 52 cited sources checked · 0 supported · 0 flagged
- Findingown data
Silencing (P)RR reduces LDL uptake in A431 and HepG2 cells cultured in complete medium containing lipoproteins.
“Silencing (P)RR also reduced LDL uptake in A431 and HepG2 cells when these were cultured in complete medium (ie, medium containing lipoproteins), even though overall uptake was much lower when compared with that in sterol-depleted cells (Online Figure IIB and IIC).”
Quote in the paperSubstantial claim - Findingown data
(P)RR interacts with SORT1.
“(Pro)renin receptor ([P]RR) interacts with sortilin-1 (SORT1) and regulates its protein abundance.”
- Also stated in: § Summary · plain
“coimmunoprecipitation of (P)RR with SORT1, but not with tumor necrosis factor receptor-associated factor 4 (TRAF4).”
- Also stated in: § Additional information · plain
“we found that it interacts with sortilin-1, a recently identified receptor for lowdensity lipoprotein.”
Quote in the paperSubstantial claim - Also stated in: § Summary · plain
- Findingown data
Reducing (P)RR mRNA levels by approximately 90% in A431 cells results in a 2-fold decrease in LDL uptake.
“In A431 cells, reducing (P)RR mRNA levels (by ≈90%) resulted in a 2-fold decrease in LDL uptake (Figure 2A-2C).”
Quote in the paperSubstantial claim - Findingown data
In the absence of added lipoproteins, disappearance of surface-biotinylated LDLR is negligible.
“In the absence of added lipoproteins, disappearance of labeled LDLR was negligible (not shown).”
Quote in the paperSubstantial claim - Findingreasoning
Silencing (P)RR reduces cellular LDL uptake.
“thereby reducing the cellular uptake of low-density lipoprotein.”
Quote in the paperSubstantial claim
- Findingown data
Silencing (P)RR in HepG2 cells decreases LDL uptake by 40%.
“Similar to A431 cells, silencing (P)RR expression in HepG2 cells decreased uptake of LDL by 40% (Figure 2D).”
Quote in the paperSubstantial claim - Findingown data
None of the lysosomal blockers reverses the degradation of SORT1 after (P)RR silencing.
“None of these lysosomal blockers reversed the degradation of SORT1 after (P)RR silencing.”
Quote in the paperSubstantial claim - Findingreasoning
Loss of PRR in the studied cells did not grossly affect V-ATPase activity.
“several additional lines of evidence suggest that loss of PRR in the studied cells did not grossly affect V-ATPase activity.”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR reduces LDL uptake in Huh7 cells to a similar extent as in HepG2 cells.
“Silencing (P)RR also reduced LDL uptake in Huh7 cells to a similar extent as in HepG2 cells (Online Figure IIE).”
Quote in the paperSubstantial claim - Findingown data
The effect of silencing (P)RR on LDL uptake is time-dependent, with further decrease when silencing is extended to 72 hours.
“Furthermore, the effect of silencing (P)RR seems to be time-dependent, as LDL uptake was further decreased when silencing was extended to 72 hours (Online Figure IID).”
Quote in the paperNot a substantial claim - Findingown data
Overexpressing (P)RR does not affect PCSK9-induced LDLR degradation.
“Accordingly, overexpressing (P) RR did not affect PCKS9-induced LDLR degradation (Online Figure VIII).”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR does not grossly affect endocytosis.
“Endocytosis of EGF receptor and transferrin receptor was not affected by (P)RR silencing.”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR decreases SORT1 protein abundance.
“Silencing the (P)RR led to decreased sortilin-1 and LDL receptor protein abundance”
- Also stated in: § Summary · plain
“(P)RR and SORT1 protein abundance was quantified and normalized to the level of β-actin in the same lysate.”
Quote in the paperSubstantial claim - Also stated in: § Summary · plain
- Findingown data
Silencing (P)RR in A431 and HepG2 cells decreases endogenous SORT1 protein abundance.
“Consistent with our initial observation in HEK293 cells, silencing of (P)RR expression in A431 and HepG2 cells also decreased the abundance of endogenous SORT1 protein (Figure 3A and 3B).”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR does not accelerate degradation of the plasma membrane LDLR pool.
“silencing (P)RR expression did not accelerate the degradation of the plasma membrane LDLR pool”
Quote in the paperSubstantial claim - Findingown data
In HepG2 and A431 cells, combined silencing of (P)RR and SORT1 does not result in an additive reduction in LDL uptake compared with depletion of (P)RR or SORT1 alone.
“In support of this concept, we found that in both HepG2 and A431 cells combined silencing of (P)RR and SORT1 did not result in an additive reduction in LDL uptake when compared with depletion of the (P)RR or SORT1 alone (Figure 3G; Online Figure IIB and IIC).”
Quote in the paperSubstantial claim - Findingown data
Overexpression of SORT1 in HepG2 cells mildly increases protein abundance of (P)RR and LDLR.
“Furthermore, we found that overexpression of SORT1 in HepG2 cells mildly increased protein abundance of (P)RR and LDLR (Online Figure V).”
Quote in the paperNot a substantial claim - Findingown data
The (P)RR post-transcriptionally controls protein abundance of SORT1.
“We show that the (P)RR post-transcriptionally controls protein abundance of SORT1, and unexpectedly that of the low-density lipoprotein receptor (LDLR).”
- Also stated in: § Results (P)RR-Interactome Reveals Potential Novel Functions of the (P)RR · plain
“Our proteomic screen therefore resulted in identification of the (P) RR as a post-transcriptional regulator of SORT1.”
Quote in the paperSubstantial claim - Also stated in: § Results (P)RR-Interactome Reveals Potential Novel Functions of the (P)RR · plain
- Findingown data
Endogenous TRAF4 does not coimmunoprecipitate with endogenous (P)RR in HEK293 cells.
“We found that SORT1, but not TRAF4, coimmunoprecipitated with endogenous (P)RR (Figure 1A).”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR in HEK293 cells decreases SORT1 protein abundance by 42%.
“Unexpectedly, this resulted in a 42% decrease in SORT1 protein abundance, reminiscent of that seen with other V-ATPase subunits (Figure 1C and 1D).12”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [12]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Findingown data
(P)RR-induced reduction in LDLR abundance is rescued by lysosomotropic agents.
“(Pro)renin receptor ([P]RR)-induced reduction in low-density lipoprotein receptor (LDLR) abundance is rescued by lysosomotropic agents.”
- Also stated in: § Discussion · plain
“we found that lysosomotropic agents reversed (P)RR-induced reduction in LDLR protein abundance”
Quote in the paperSubstantial claim - Also stated in: § Discussion · plain
- Findingown data
Blocking autophagy and the proteasome with 3-Methyladenine or MG132 fails to rescue SORT1 protein after (P)RR silencing.
“Unexpectedly, blocking the 2 other major degradation pathways, autophagy, and the proteasome (using 3-Methyladenine or MG132, respectively), also failed to rescue SORT1 protein (Online Figure VI).”
Quote in the paperSubstantial claim - Findingcitation
The proteomic screen identified several V-ATPase components known to interact with (P)RR.
“In this set of proteins we found several V-ATPase components, including those known to interact with (P)RR, 17 which validates our proteomics approach”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [17]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Findingown data
The (P)RR post-transcriptionally controls protein abundance of the low-density lipoprotein receptor (LDLR).
“We show that the (P)RR post-transcriptionally controls protein abundance of SORT1, and unexpectedly that of the low-density lipoprotein receptor (LDLR).”
- Also stated in: § (P)RR Controls Stability of the LDLR Protein and LDL Uptake · hedged
“These results point toward the (P)RR acting as a post-transcriptional regulator of the LDLR”
Quote in the paperSubstantial claim - Also stated in: § (P)RR Controls Stability of the LDLR Protein and LDL Uptake · hedged
- Findingown data
Apart from V-ATPase subunits, the (P)RR interactome contains several interacting partners with low frequency in CRAPome that are involved in signal transduction, lipid metabolism, mitochondrial transport, and protein folding.
“Apart from V-ATPase subunits, we found several (P)RR-interacting partners with low frequency in CRAPome that are involved, among others, in signal transduction, lipid metabolism, mitochondrial transport, and protein folding.”
Quote in the paperNot a substantial claim - Findingown data
Silencing (P)RR in HEK293 cells does not change SORT1 transcript level.
“Importantly, this occurred in the absence of changes in SORT1 transcript level (Figure 1E).”
Quote in the paperSubstantial claim - Findingown data
Mapping the (P)RR-interactome identified SORT1 as a novel (P)RR-interacting partner.
“We mapped the (P)RR-interactome and identified sortilin 1 (SORT1) as Molecular Medicine”
- Also stated in: § Results (P)RR-Interactome Reveals Potential Novel Functions of the (P)RR · plain
“From the identified proteins, SORT1 is the candidate with the highest Mascot score, and it is not found in the CRAPome.”
Quote in the paperSubstantial claim - Also stated in: § Results (P)RR-Interactome Reveals Potential Novel Functions of the (P)RR · plain
- Findingown data
LDL uptake in several cell types is sensitive to (P)RR levels.
“We demonstrate that as a consequence LDL uptake in several cell types is sensitive to (P)RR levels.”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR decreases LDLR protein abundance.
“Silencing the (P)RR led to decreased sortilin-1 and LDL receptor protein abundance”
- Also stated in: § Summary · plain
“and LDLR cell-surface density (Figures 3E and 3F) without affecting SORT1 and LDLR mRNA expression (Online Figure IVC and IVD).”
Quote in the paperSubstantial claim - Also stated in: § Summary · plain
- Findingown data
When lipoprotein-containing medium is added, disappearance of the LDLR or transferrin receptor from the plasma membrane is unchanged despite effective (P)RR silencing reducing total cellular LDLR levels.
“Similarly, when lipoprotein-containing medium was added, even though effective (P)RR silencing reduced total cellular LDLR levels, disappearance of the LDLR or transferrin receptor (as control) from the plasma membrane was unchanged (Online Figure VII).”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR reduces total LDLR abundance in A431 and HepG2 cells.
“In line with this, we found that next to reducing SORT1 levels, silencing of (P)RR also reduced total LDLR abundance (Figures 3A and 3B; Online Figure IVA”
Quote in the paperSubstantial claim - Findingreasoning
Silencing (P)RR has no effect on TRAF4 levels.
“In addition, in agreement with the absence of an interaction between (P)RR and TRAF4 we observed no effect of silencing (P)RR on TRAF4 levels (not shown).”
Quote in the paperNot a substantial claim - Findingown data
Three lysosomotropic agents, bafilomycin A1, NH4Cl, and chloroquine, rescue LDLR levels after (P)RR silencing.
“These results point toward the (P)RR acting as a post-transcriptional regulator of the LDLR and consistent with this notion 3 different lysosomotropic agents, bafilomycin A1 (BafA1), NH 4 Cl, and chloroquine rescued LDLR levels after (P)RR silencing (Figure 4).”
Quote in the paperSubstantial claim - Findingown data
The TAP-based proteomic screen in HEK293 cells identified 40 proteins that copurified with N-terminally TAP-tagged (P)RR in 2 independent purifications but not with the tag only.
“We identified 40 proteins that copurified with N-terminally TAP-tagged (P)RR in 2 independent purifications (Online Table III), but not with the tag only.”
Quote in the paperSubstantial claim - Findingown data
Endogenous SORT1 and endogenous (P)RR coimmunoprecipitate with each other in HEK293 cells.
“We found that SORT1, but not TRAF4, coimmunoprecipitated with endogenous (P)RR (Figure 1A).Conversely, (P)RR also coimmunoprecipitated with endogenous SORT1 (Figure 1B), establishing the (P)RR-SORT1 interaction.”
Quote in the paperSubstantial claim - Findingown data
EGF uptake in A431 cells is not affected by (P)RR silencing at either low or high EGF doses.
“Irrespective of the dose, silencing of (P)RR expression did not affect EGF uptake in A431 cells (Online Figure IIIC and IIID).”
Quote in the paperSubstantial claim - Findingown data
Silencing (P)RR does not affect lysosomal targeting of LDLR by exogenous PCSK9.
“or affected lysosomal targeting of the LDLR by exogenous proprotein convertase subtilisin/kexin type 9.”
Quote in the paperSubstantial claim - Interpretationown data
The (P)RR acts as a post-transcriptional regulator of the LDLR.
“These results point toward the (P)RR acting as a post-transcriptional regulator of the LDLR”
Quote in the paperSubstantial claim - Interpretationown data
The LDLR is necessary for the large effect of (P)RR on LDL uptake.
“suggesting that the LDLR is necessary for the large effect of (P)RR on LDL uptake.”
Quote in the paperSubstantial claim - Interpretationreasoning
Under the sterol depletion regimen and LDL concentration used, the primary entry portal for LDL internalization is highly likely the LDLR, not SORT1.
“In fact, under the sterol depletion regimen and the LDL concentration (5 µg/mL) we used in these experiments, it is highly likely that the primary entry portal for LDL internalization would be the LDLR, and not SORT1.”
Quote in the paperSubstantial claim - Interpretationown data
(P)RR depletion is unlikely to affect V-ATPase only in a subset of LDLR-enriched endocytic vesicles.
“We find it also unlikely that (P) RR depletion affects the V-ATPase only in a subset of LDLRenriched endocytic vesicles as our kinetic analysis of plasma membrane removal of the LDLR revealed no major alterations after silencing of (P)RR.”
Quote in the paperSubstantial claim - Premisenone given
There is no report indicating that SORT1 can affect LDLR levels.
“Despite the existence of strong evidence linking SORT1 to LDL-cholesterol metabolism in humans, 28,29,31 to the best of our knowledge there is no report indicating that SORT1 can affect LDLR levels.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [28]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [31]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationown data
The (P)RR controls an event required for proper trafficking or recycling of the LDLR to the plasma membrane.
“Therefore, our results rather point toward an event controlled by the (P)RR, which is required for proper trafficking or recycling of the LDLR to the plasma membrane.”
Quote in the paperSubstantial claim - Interpretationown data
The N-terminally TAP-tagged (P)RR is at least functional for interacting with the V-ATPase.
“which validates our proteomics approach and suggests that the N-terminally TAP-tagged (P)RR is at least functional for interacting with the V-ATPase.”
Quote in the paperNot a substantial claim - Premisecitation
The physiological relevance of the (pro)renin-(P)RR interaction is questionable because the (pro)renin concentrations required are more than 1000-fold higher than those observed under (patho)physiological conditions.
“However, the physiological relevance of the (pro)renin-(P)RR interaction is questionable because the (pro)renin concentrations required are >1000× higher than observed under (patho) physiological conditions.7,8”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [8]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationown data
A functional (P)RR-SORT1 interaction does not require the presence of the LDLR.
“Similar to the other cell lines, silencing (P)RR expression reduced SORT1 abundance in LDLA7 cells, and vice versa, implying that a functional (P)RR-SORT1 interaction does not require the presence of the LDLR (Figure 3C).”
Quote in the paperSubstantial claim - Interpretationreasoning
The results may provide an explanation why genetic ablation or silencing of SORT1 resulted in a less pronounced increase in plasma LDL-cholesterol on an Ldlr-/- background.
“In addition, our results may also provide an explanation why genetic ablation or silencing of SORT1 resulted in a less pronounced increase in plasma LDLcholesterol on a Ldlr -/-background.29,41”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [41]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationown data
The (P)RR represents a previously unrecognized regulator of LDL metabolism.
“Collectively, our results indicate that the (P)RR represents a previously unrecognized regulator of LDL metabolism.”
- Also stated in: § Discussion · plain
“In this study, using an unbiased proteomics approach, we identify a novel role for the (P)RR in LDL metabolism.”
Quote in the paperSubstantial claim - Also stated in: § Discussion · plain
- Interpretationown data
The (P)RR is a post-transcriptional regulator of SORT1.
“Our proteomic screen therefore resulted in identification of the (P) RR as a post-transcriptional regulator of SORT1.”
Quote in the paperSubstantial claim - Study design and conductown data
The decrease in LDL uptake after (P)RR silencing in A431 cells is not an off-target effect, as two additional siRNAs reduce LDL uptake to the same extent.
“To rule out the possibility that this is an off-target effect, we silenced (P)RR expression in these cells using 2 additional siRNAs.Both siRNAs reduced LDL uptake to the same extent (Online Figure IIA), confirming that the decrease in LDL uptake is because of reduced (P)RR expression.”
Quote in the paperSubstantial claim - Interpretationreasoning
A general acidification defect of the endolysosomal compartment does not occur after (P)RR silencing in the studied cells.
“our findings suggest that a general acidification defect of the endolysosomal compartment does not occur after (P)RR silencing in the cells we studied”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationown data
The effect of (P)RR on the LDLR is distinct from that mediated by the ubiquitin ligase inducible degrader of the LDLR and proprotein convertase subtilisin/kexin type 9, which induce specific removal of the LDLR from the membrane and target the receptor for lysosomal degradation.
“In this, the effect of (P) RR seems to be distinct from that mediated by the ubiquitin ligase inducible degrader of the LDLR and proprotein convertase subtilisin/kexin type 9, which induce specific removal of the LDLR from the membrane and target the receptor for lysosomal degradation.20,36,37”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [20]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [36]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [37]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Mutations in the (P)RR gene might associate with circulating LDL levels.
“suggests that mutations in the (P)RR gene might associate with circulating LDL levels.”
Quote in the paperNot a substantial claim - Interpretationown data
The current study reveals a previously unrecognized function of SORT1 in regulating LDLR protein levels in hepatocytes.
“Our current study also reveals a previously unrecognized function of SORT1 in regulating LDLR protein levels in hepatocytes.”
Quote in the paperSubstantial claim
- It may state two separate claims as one. 29
- Probably not a substantial claim. 19
It may state two separate claims as one.
Findingown dataSilencing SORT1 reduces cellular LDLR abundance to an extent comparable with (P)RR silencing and attenuates LDL uptake.
“Unexpectedly, in these experiments we found that silencing SORT1 also effectively reduced cellular LDLR abundance to an extent comparable with that achieved by (P)RR silencing, and as a consequence also resulted in attenuated LDL uptake (Figure 3G; Online Figure IIB-IIE).”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataTransferrin uptake in A431 and HepG2 cells is not decreased after (P)RR silencing; it is slightly increased in A431 cells.
“Consistent with this, and in contrast to the observed effects on LDL uptake, transferrin uptake in A431 and HepG2 cells was not decreased (Figure 2E and 2F; Online Figure IIIB).In fact, transferrin uptake was slightly increased in A431 cells after (P)RR silencing (Figure 2F).”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataSORT1 is the candidate with the highest Mascot score in the (P)RR interactome and is not found in the CRAPome.
“From the identified proteins, SORT1 is the candidate with the highest Mascot score, and it is not found in the CRAPome.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataIn LDLA7 cells, silencing (P)RR or SORT1 significantly reduces LDL uptake, but the reduction is minimal and attenuated compared with the effect in other cells tested.
“Overall LDL uptake in LDLA7 cells is low, but nevertheless silencing (P) RR or SORT1 significantly reduced LDL uptake in these cells.However, this reduction was minimal and attenuated in comparison with the effect that silencing these genes had in the other cells tested (Figure 3D, and compare with Figure 2C and 2D)”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataSilencing (P)RR in A431 cells does not influence abundance of either the transferrin receptor or the EGF receptor.
“Silencing of (P)RR expression in A431 cells did not influence abundance of either the transferrin receptor or the EGF receptor (Online Figure IIIA).”
Quote in the paperSubstantial claimProbably not a substantial claim. The paper’s conclusions may not depend on it.
FindingcitationMany proteins found in the (P)RR interactome, especially transporters, are also present at high frequency in other purifications in the CRAPome.
“Many proteins found in our profile, especially transporters, are also present at high frequency in other purifications in the CRAPome.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [22]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
Findingown dataSORT1 depletion leads to a comparable reduction in cellular LDL uptake and decreased (P)RR abundance reciprocally.
“Similarly, SORT1 depletion led to a comparable reduction in cellular LDL uptake and decreased (P)RR abundance reciprocally.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataThe (P)RR-SORT1 interaction controls LDLR protein stability and LDL uptake.
“The (Pro)renin receptor ([P]RR)sortilin-1 (SORT1) interaction controls lowdensity lipoprotein (LDL) receptor (LDLR) protein stability and LDL uptake.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataIn LDLA7 cells, silencing (P)RR reduces SORT1 abundance, and silencing SORT1 reduces (P)RR abundance.
“Similar to the other cell lines, silencing (P)RR expression reduced SORT1 abundance in LDLA7 cells, and vice versa, implying that a functional (P)RR-SORT1 interaction does not require the presence of the LDLR (Figure 3C).”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown data(P)RR silencing reduces LDLR cell-surface density without affecting SORT1 and LDLR mRNA expression.
“and LDLR cell-surface density (Figures 3E and 3F) without affecting SORT1 and LDLR mRNA expression (Online Figure IVC and IVD).”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown data(P)RR silencing successfully suppresses (P)RR mRNA levels and does not affect SORT1 mRNA levels.
“(P)RR silencing in HEK293 cells successfully suppresses (P) RR mRNA levels, and does not affect SORT1 mRNA levels; n=6, ***P<0.001.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
PremisecitationDepletion of the (P)RR results in decreased protein levels of V-ATPase subunits, impaired acidification of intracellular compartments, and defects in autophagy.
“Depletion of the (P)RR results in decreased protein levels of V-ATPase subunits, impaired acidification of intracellular compartments, and defects in autophagy.[12][13][14]”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [12]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [14]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. It may state two separate claims as one.
PremisecitationSORT1 has been identified as an important determinant of LDL metabolism and of circulating levels of LDL in humans.
“SORT1 is implicated in several cellular functions, 26,27 and it has recently been identified as an important determinant of LDL metabolism, [28][29][30] and of circulating levels of LDL in humans.29,31”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [28]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [30]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
Premisecitation(Pro)renin-independent functions for (P)RR have been reported, including a function as an accessory protein of the vacuolar H+-ATPase (V-ATPase).
“Recently, (pro)renin-independent functions for (P)RR have been reported, including a function as an accessory protein of the vacuolar H + -ATPase (V-ATPase).9”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
Interpretationown dataThe main finding of the study is the identification of (P)RR as a post-transcriptional regulator of LDLR abundance and LDL uptake into cells, plausibly by regulating trafficking of the receptor to the plasma membrane.
“The main finding of this study is the identification of (P)RR as a post-transcriptional regulator of LDLR abundance of LDL uptake into cells, plausibly by regulating trafficking of the receptor to the plasma membrane.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
InterpretationcitationThe finding that SORT1 regulates LDLR protein levels is consistent with recent reports demonstrating that SORT1 deficiency leads to increased plasma LDL cholesterol and provides an additional mechanism that may contribute to this outcome.
“This finding is consistent with recent reports demonstrating that SORT1 deficiency leads to increased plasma LDL cholesterol, 29,40 and provides an additional mechanism that may contribute to this outcome.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [40]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
Interpretationown dataOverexpression of SORT1 is not sufficient to overcome degradation of the LDLR induced by silencing (P)RR, indicating that this outcome is not solely dependent on reduced SORT1 protein.
“However, this was not sufficient to overcome degradation of the LDLR induced by silencing (P)RR, indicating that this outcome is not solely dependent on reduced SORT1 protein.”
Quote in the paperSubstantial claimProbably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationSilencing of SORT1 results in a less pronounced increase in plasma LDL-cholesterol on an Ldlr-/- background.
“or silencing of SORT1 resulted in a less pronounced increase in plasma LDLcholesterol on a Ldlr -/-background.29,41”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [41]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
Interpretationown data(P)RR depletion affects LDL metabolism in multiple cell lines, suggesting that the (P)RR is a common regulator of LDL metabolism.
“Taken together, these data show that (P)RR depletion affects LDL metabolism in multiple cell lines, suggesting that the (P)RR is a common regulator of LDL metabolism.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Interpretationown dataRegulation of LDLR by (P)RR is a post-transcriptional event culminating in lysosomal degradation of LDLR.
“Our study demonstrates that regulation of the LDLR by the (P)RR is a post-transcriptional event culminating in lysosomal degradation of the LDLR.”
Quote in the paperSubstantial claimProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
PremisecitationTRAF4 can mediate activation of Erk1/2, Akt, and Wnt/β-catenin signaling, all of which have been recently suggested to be modulated by (P)RR.
“Tumor necrosis factor receptor-associated factor 4 (TRAF4), despite having a Mascot score in the lower range was another attractive candidate, as it can mediate activation of Erk1/2, Akt, and Wnt/β-catenin signaling, [23][24][25] all of which have been”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [23]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [24]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
Interpretationown data(P)RR depletion does not grossly attenuate clathrin-dependent endocytosis and differentially affects endocytosis of cargo, largely attenuating LDL uptake yet sparing EGF and transferrin internalization.
“Taken together, these results indicate that (P)RR depletion does not grossly attenuate clathrin-dependent endocytosis and that (P)RR differentially affects endocytosis of cargo, largely attenuating LDL uptake yet sparing EGF and transferrin internalization.”
Quote in the paperSubstantial claimProbably not a substantial claim. It may state two separate claims as one.
PremisecitationSORT1 can directly bind LDL and mediate LDL internalization in hepatocytes and macrophages.
“Recent studies from the Rader Laboratory have shown that SORT1 can directly bind LDL and mediate LDL internalization in hepatocytes 28 and macrophages.34”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [28]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [34]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
PremisecitationIn experimental assays, (pro)renin-(P)RR signaling results in extracellular signal-regulated kinase 1/2 (Erk1/2) activation and upregulation of profibrotic factors such as transforming growth factor β, collagen, and fibronectin.
“In experimental assays (pro)renin-(P)RR signaling results in extracellular signal-regulated kinase 1/2 (Erk1/2) activation, and as a consequence upregulation of profibrotic factors, such as transforming growth factor β, collagen, and fibronectin.[2][3][4][5][6]”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
Interpretationown data(P)RR is a previously unrecognized regulator of LDL metabolism, which specifically regulates cellular LDL uptake by modulating LDLR protein abundance.
“we report that the (P)RR is a previously unrecognized regulator of LDL metabolism, which specifically regulates cellular LDL uptake by modulating LDLR protein abundance.”
Quote in the paperSubstantial claim- Rests on an assumption: (P)RR has renin-angiotensin system-independent functions.
Probably not a substantial claim. It may state two separate claims as one.
PremisecitationV-ATPases are multisubunit complexes expressed virtually in all cell types and play an important role in protein trafficking, receptor recycling, and lysosomal degradation by acidifying intracellular compartments.
“V-ATPases are multisubunit complexes, and they are expressed virtually in all cells types.They play an important role in protein trafficking, receptor recycling, and lysosomal degradation by acidifying intracellular compartments.10,11”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [10]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [11]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
PremisecitationThe (P)RR is required for both prorenin-dependent and prorenin-independent regulation of V-ATPase activity in collecting duct cells.
“Accordingly, we previously reported that the (P)RR is required for both prorenin-dependent and proreninindependent regulation of V-ATPase activity in collecting duct cells.15”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [15]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The authors may not put it forward as true. The paper’s conclusions may not depend on it.
InterpretationreasoningThe functional interaction of (P)RR and SORT1 serves to ensure proper trafficking of nascent LDLR to the plasma membrane.
“an alternative explanation for our observations may be that the functional interaction of the (P)RR and SORT1 serves to ensure proper trafficking of nascent LDLR to the plasma membrane.”
Quote in the paperNot a substantial claim- Rests on an assumption: Sortilin-1 is a receptor for low-density lipoprotein.
It may state two separate claims as one.
Interpretationown dataReversal by lysosomotropic agents indicates an intact endolysosomal pH gradient and functional lysosomes.
“indicating the existence of an intact endolysosomal pH gradient and functional lysosomes.”
Quote in the paperSubstantial claimProbably not a substantial claim.
PremisecitationEndocytosis of LDL via the LDLR pathway is a clathrin-dependent process.
“Endocytosis of LDL via the LDLR pathway is a clathrindependent process.32”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationThe (P)RR has been implicated in canonical Wnt and PCP signaling.
“The (P)RR has been also recently implicated in canonical Wnt and PCP signaling, [16][17][18] emphasizing the notion that our understanding of (P)RR function remains incomplete.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [16]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [17]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [18]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationSORT1 controls LDLR activity.
“The ability of SORT1 to control LDLR activity hints that it may influence efficacy of statins by regulating LDLR activity.”
Quote in the paperNot a substantial claimProbably not a substantial claim. It may state two separate claims as one.
PremisecitationSORT1 controls hepatic very low-density lipoprotein secretion and can bind and internalize LDL directly, serving as a major regulator in determining plasma LDL levels.
“SORT1 controls hepatic very low-density lipoprotein secretion, and can also bind and internalize LDL directly, thereby serving as a major regulator in determining plasma LDL levels.28,29,34”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [28]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [34]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationGenetic variances in the SORT1 locus are associated with the LDL-cholesterol response to statin therapy.
“a recent meta-analysis study found that genetic variances in the SORT1 locus are associated with the LDL-cholesterol response to statin therapy.42”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [42]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
PremisecitationSORT1 promotes both apolipoprotein B secretion and degradation in hepatocytes.
“SORT1 has been demonstrated to promote both apolipoprotein B secretion and degradation in hepatocytes.28,48”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [28]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [48]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim.
Premisenone givenSortilin-1 controls LDL receptor protein abundance.
“Sortilin-1 not only acts as a receptor for low-density lipoprotein, but also controls LDL receptor protein abundance.”
Quote in the paperSubstantial claimProbably not a substantial claim.
PremisecitationSORT1 has an established role in intracellular trafficking of apolipoprotein B, PCSK9, Trk, and Glut4.
“Given the established role of SORT1 in intracellular trafficking of apolipoprotein B, proprotein convertase subtilisin/kexin type 9, Trk, and Glut4, 28,[43][44][45]”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [28]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [43]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [44]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
PremisecitationDepleting (P)RR in podocytes decreases the level of V-ATPase subunits, leading to autophagosomal defects.
“previous studies demonstrated that depleting the (P)RR in podocytes decreases the level of V-ATPase subunits leading to autophagosomal defects.13,14”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [14]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
PremisecitationMacrophages lacking PRR do not display altered acidification and phagolysosomal defects.
“Kissing et al 47 recently reported that macrophages lacking PRR do not display altered acidification and phagolysosomal defects.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [47]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
The paper relies on this without support.
(P)RR has renin-angiotensin system-independent functions.
“The (P)RR is now believed to largely have renin-angiotensin system-independent functions.”
The paper relies on this without support.
Sortilin-1 is a receptor for low-density lipoprotein.
“sortilin-1, a recently identified receptor for lowdensity lipoprotein.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increased ApoB concentrations caused by hepatic (P)RR inhibition are likely a result of reduced sortilin-1 abundance.
“Since sortilin-1 promotes ApoB degradation and the (P)RR inhibition reduces sortilin-1 abundance (6, 7, 26), increased ApoB is likely a result of reduced sortilin-1 abundance.”
From (Pro)renin Receptor Inhibition Reduces Plasma Cholesterol and Triglycerides but Does Not Attenuate Atherosclerosis in Atherosclerotic Mice (2021) · cites this paper as [6]
Silencing (P)RR expression in hepatocytes in vitro reduces protein abundance of SORT1 and LDLR post-transcriptionally and consequently cellular LDL uptake.
“and demonstrated that silencing (P)RR expression in hepatocytes in vitro reduces protein abundance of SORT1 and LDLR post-transcriptionally, and consequently cellular LDL uptake.”
From (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis (2018) · cites this paper as [31]
The (P)RR is a SORT1-interacting protein.
“Moreover, we have recently identified the (P)RR as a SORT1-interacting protein31”
From (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis (2018) · cites this paper as [31]
(P)RR is a novel modulator of LDL metabolism in vitro.
“We recently reported that the (P)RR is a novel modulator of LDL metabolism in vitro.31”
From (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis (2018) · cites this paper as [31]
(P)RR inhibition regulates PDH abundance via an as yet unsolved mechanism.
“This may suggest that (P)RR inhibition regulates PDH abundance via an as yet unsolved mechanism, as seems to be the case with SORT1 as well.31”
From (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis (2018) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Figure 3D is described as both an immunoblot and an LDL uptake measurement
MinorThe caption first includes panel D among the immunoblot panels, then identifies panel D as a quantitative LDL uptake measurement.
“C and D, LDLA7 CHO cells were transfected with control, (P)RR, or SORT1 siRNA for 48 hours.Total cell lysates were immunoblotted as indicated and a representative blot of 3 independent experiments is shown.”
“D, LDLA7 CHO cells were treated as indicated above, and subsequently cultured with Dylight488-labeled LDL for an additional 3 hours.Quantitative measurement of LDL uptake is shown; n=9, *P<0.05,**P<0.01.”
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
The CRAPome: a contaminant repository for affinity purification–mass spectrometry data
Mellacheruvu, D., Wright, Z., Couzens, A. L., Lambert, J.-P., St-Denis, N. A., Li, T., Miteva, Y. V., Hauri, S., Sardiu, M. E., Low, T. Y., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2557 · Cited by 1,686
Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology
Forgac, M. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2272 · Cited by 1,626
Nguyen, G., Delarue, F., Burcklé, C., Bouzhir-Sima, L., Giller, T., & Sraer, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14276 · Cited by 1,276
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus
Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N. E., Ahfeldt, T., Sachs, K. V., Li, X., Li, H., Kuperwasser, N., Ruda, V. M., et al. (2010) · Nature · doi:10.1038/nature09266 · Cited by 1,140
ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75NTRand Sortilin
Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., Kermani, P., Torkin, R., Chen, Z.-Y., Lee, F. S., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5123-04.2005 · Cited by 1,013
LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Self-citationClathrin-independent endocytosis of ubiquitinated cargos
Sigismund, S., Woelk, T., Puri, C., Maspero, E., Tacchetti, C., Transidico, P., Di Fiore, P. P., & Polo, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409817102 · Cited by 739
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
Self-citationSecreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Requirement of Prorenin Receptor and Vacuolar H + -ATPase–Mediated Acidification for Wnt Signaling
Cruciat, C.-M., Ohkawara, B., Acebron, S. P., Karaulanov, E., Reinhard, C., Ingelfinger, D., Boutros, M., & Niehrs, C. (2010) · Science · doi:10.1126/science.1179802 · Cited by 516
Anderson, R. G. W., Brown, M. S., & Goldstein, J. L. (1977) · Cell · doi:10.1016/0092-8674(77)90022-8 · Cited by 489
Huang, Y., Wongamorntham, S., Kasting, J., McQuillan, D. J., Owens, R. T., Yu, L. H., Noble, N. A., & Border, W. A. (2005) · Kidney International · doi:10.1038/sj.ki.5000011 · Cited by 426
Regulation and Isoform Function of the V-ATPases
Toei, M., Saum, R., & Forgac, M. D. (2010) · Biochemistry · doi:10.1021/bi100397s · Cited by 393
Ludwig, J., Kerscher, S., Brandt, U., Pfeiffer, K., Getlawi, F., Apps, D. K., & Schägger, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.18.10939 · Cited by 300
Ichihara, A., Suzuki, F., Nakagawa, T., Kaneshiro, Y., Takemitsu, T. Y., Sakoda, M., Nabi, A. H. M. N., Nishiyama, A., Sugaya, T., Hayashi, M., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010029 · Cited by 286
Kinouchi, K., Ichihara, A., Sano, M., Sun-Wada, G.-H., Wada, Y., Kurauchi-Mito, A., Bokuda, K., Narita, T., Oshima, Y., Sakoda, M., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.224667 · Cited by 282
Sort1, Encoded by the Cardiovascular Risk Locus 1p13.3, Is a Regulator of Hepatic Lipoprotein Export
Kjolby, M., Andersen, O. M., Breiderhoff, T., Fjorback, A. W., Pedersen, K. M., Madsen, P., Jansen, P., Heeren, J., Willnow, T. E., & Nykjaer, A. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.08.006 · Cited by 269
Postmus, I., Trompet, S., Deshmukh, H., Barnes, M. R., Li, X., Warren, H. R., Chasman, D. I., Zhou, K., Arsenault, B. J., Donnelly, L. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6068 · Cited by 268
Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism
Strong, A., Ding, Q., Edmondson, A. C., Millar, J. S., Sachs, K. V., Li, X., Kumaravel, A., Wang, M. Y., Ai, D., Guo, L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63563 · Cited by 222
Batenburg, W. W., Krop, M., Garrelds, I. M., VRIES, R. D., de Bruin, R. J., Burcklé, C., Müller, D. N., Bäder, M., Nguyen, G., & Danser, A. J. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f05bae · Cited by 222
Self-citationSortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling
Vægter, C. B., Jansen, P., Fjorback, A. W., Glerup, S., Skeldal, S., Kjølby, M., Richner, M., Erdmann, B., Nyengaard, J. R., Tessarollo, L., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2689 · Cited by 205
Macrophage Sortilin Promotes LDL Uptake, Foam Cell Formation, and Atherosclerosis
Patel, K. M., Strong, A., Tohyama, J., Jin, X., Morales, C. R., Billheimer, J., Millar, J., Kruth, H., & Rader, D. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.305811 · Cited by 194
Kingsley, D. M., & Krieger, M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.17.5454 · Cited by 180
Prorenin receptor is essential for podocyte autophagy and survival
Riediger, F., Quack, I., Qadri, F., Hartleben, B., Park, J.-K., Potthoff, S. A., Sohn, D., Sihn, G., Rousselle, A., Fokuhl, V., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011020200 · Cited by 178
Prorenin Receptor Is Essential for Normal Podocyte Structure and Function
Oshima, Y., Kinouchi, K., Ichihara, A., Sakoda, M., Kurauchi-Mito, A., Bokuda, K., Narita, T., Kurosawa, H., Sun-Wada, G.-H., Wada, Y., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011020202 · Cited by 173
The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion
Gustafsen, C., Kjolby, M., Nyegaard, M., Mattheisen, M., Lundhede, J., Buttenschøn, H., Mors, O., Bentzon, J. F., Madsen, P., Nykjaer, A., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.006 · Cited by 170
Linsel-Nitschke, P., Heeren, J., Aherrahrou, Z., Bruse, P., Gieger, C., Illig, T., Prokisch, H., Heim, K., Doering, A., Peters, A., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.034 · Cited by 141
Wnt/Frizzled Signaling Requires dPRR, the Drosophila Homolog of the Prorenin Receptor
Buechling, T., Bartscherer, K., Ohkawara, B., Chaudhary, V., Spirohn, K., Niehrs, C., & Boutros, M. (2010) · Current Biology · doi:10.1016/j.cub.2010.05.028 · Cited by 117
Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice
Ai, D., Baez, J. M., Jiang, H., Conlon, D., Hernández‐Ono, A., Frank-Kamenetsky, M. D., Milstein, S., Fitzgerald, K. J., Murphy, A. J., Woo, C. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61248 · Cited by 114
TRAF4 Is a Critical Molecule for Akt Activation in Lung Cancer
Li, W., Peng, C., Lee, M., Lim, D., Zhu, F., Fu, Y., Yang, G., Sheng, Y., Xiao, L., Dong, X., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0913 · Cited by 112
BACE1 Retrograde Trafficking Is Uniquely Regulated by the Cytoplasmic Domain of Sortilin
Finan, G. M., Okada, H., & Kim, T.-W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.170217 · Cited by 104
Batenburg, W. W., de Bruin, R. J., van Gool, J. M. G., Müller, D. N., Bäder, M., Nguyen, G., & Danser, A. H. J. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.164210 · Cited by 95
Self-citationVacuolar ATPase in Phagosome-Lysosome Fusion
Kissing, S., Hermsen, C., Repnik, U., Nesset, C. K., von Bargen, K., Griffiths, G., Ichihara, A., Lee, B. S., Schwake, M., Brabander, J. K. D., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.628891 · Cited by 93
Sortilin and lipoprotein metabolism
Strong, A., Patel, K. M., & Rader, D. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000110 · Cited by 78
Vacuolar H+-ATPase meets glycosylation in patients with cutis laxa
Guillard, M., Dimopoulou, A., Fischer‐Zirnsak, B., Morava, É., Lefeber, D. J., Kornak, U., & Wevers, R. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.009 · Cited by 73
Sorrentino, V., Nelson, J. K., Maspero, E., Marques, A. R. A., Scheer, L., Polo, S., & Zelcer, N. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m037713 · Cited by 68
Self-citationZhang, J., Noble, N. A., Border, W. A., Owens, R. T., & Huang, Y. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90264.2008 · Cited by 60
Shi, J., & Kandror, K. V. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608971200 · Cited by 59
Batenburg, W. W., Lu, X., Leijten, F., Maschke, U., Müller, D. N., & Danser, A. H. J. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.180737 · Cited by 59
Self-citation(Pro)renin and its receptors: pathophysiological implications
Batenburg, W. W., & Danser, A. H. J. (2012) · Clinical Science · doi:10.1042/cs20120042 · Cited by 58
Self-citationHermle, T. F., Guida, M. C., Beck, S., Helmstädter, S., & Simons, M. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.323 · Cited by 57
Sortilins: new players in lipoprotein metabolism
Willnow, T. E., Kjølby, M., & Nykjær, A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283416f2b · Cited by 54
Lu, X., Garrelds, I. M., Wagner, C. A., Danser, A. H. J., & Meima, M. E. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00037.2013 · Cited by 41
Self-citationEtxebarria, A., Benito‐Vicente, A., Alves, A. C., Ostolaza, H., Bourbon, M., & Martı́n, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112677 · Cited by 40
Kedinger, V., Alpy, F., Baguet, A., Polette, M., Stoll, I., Chenard, M., Tomasetto, C., & Rio, M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003518 · Cited by 29
Tall, A. R., & Ai, D. (2011) · Circulation Research · doi:10.1161/res.0b013e31820d7daa · Cited by 26
Wang, A., Wang, J., Ren, H., Yang, F., Sun, L., Diao, K., Zhao, Z., Song, M., Cui, Z., Wang, E., et al. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2127-y · Cited by 21
Flagged first, then by citations
Cited by
Sorted by citations
The (pro)renin receptor in health and disease
Ichihara, A., & Yatabe, M. S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0160-5 · Cited by 137
Site-1 protease is required for the generation of soluble (pro)renin receptor
Nakagawa, T., Suzuki-Nakagawa, C., Watanabe, A., Asami, E., Matsumoto, M., Nakano, M., Ebihara, A., Uddin, M. N., & Suzuki, F. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw080 · Cited by 99
Sorting through the extensive and confusing roles of sortilin in metabolic disease
Mitok, K. A., Keller, M. P., & Attie, A. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100243 · Cited by 60
Revisiting the Brain Renin-Angiotensin System—Focus on Novel Therapies
Ren, L., Lu, X., & Danser, A. H. J. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0937-8 · Cited by 60
Self-citationRen, L., Sun, Y., Lu, H., Ye, D., Han, L., Wang, N., Daugherty, A., Li, F., Wang, M., Su, F., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312422 · Cited by 59
Self-citationThe (pro)renin receptor: an emerging player in hypertension and metabolic syndrome
Ramkumar, N., & Kohan, D. E. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.042 · Cited by 53
Tang, F.-L., Zhao, L., Zhao, Y., Sun, D., Zhu, X.-J., Mei, L., & Xiong, W.-C. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0487-2 · Cited by 47
Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases
Gao, A., Cayabyab, F. S., Chen, X., Yang, J., Wang, L., Peng, T., & Lv, Y. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3853 · Cited by 43
Angiotensin generation in the brain: a re-evaluation
Uijl, E., Ren, L., & Danser, A. H. J. (2018) · Clinical Science · doi:10.1042/cs20180236 · Cited by 36
Self-citationHu, D., Yang, Y., & Peng, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.064 · Cited by 35
Chu, A., Zirngibl, R. A., & Manolson, M. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136934 · Cited by 34
Hoffmann, N., & Peters, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105922 · Cited by 33
Binger, K. J., Neukam, M., Tattikota, S. G., Qadri, F., Puchkov, D., Willmes, D. M., Wurmsee, S., Geisberger, S., Dechend, R., Raile, K., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903678116 · Cited by 28
Megalin: a Novel Determinant of Renin-Angiotensin System Activity in the Kidney?
Sun, Y., Lu, X., & Danser, A. H. J. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01037-1 · Cited by 25
Self-citation(Pro)renin receptor as a therapeutic target for the treatment of cardiovascular diseases?
Sun, Y., Danser, A. H. J., & Lu, X. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.016 · Cited by 20
Self-citationThe prorenin receptor and its soluble form contribute to lipid homeostasis
Gatineau, E., Arthur, G., Poupeau, A., Nichols, K., Spear, B. T., Shelman, N. R., Graf, G. A., Temel, R. E., & Yiannikouris, F. B. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00135.2020 · Cited by 19
The Soluble (Pro)Renin Receptor in Health and Diseases: Foe or Friend?
Qin, M., Xu, C., & Yu, J. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000576 · Cited by 17
Cruz‐López, E. O., Uijl, E., & Danser, A. H. J. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001027 · Cited by 16
Self-citationProrenin periconceptionally and in pregnancy: Does it have a physiological role?
Wiegel, R. E., von Versen‐Höynck, F., Steegers‐Theunissen, R. P. M., Steegers, E. A. P., & Danser, A. H. J. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111118 · Cited by 15
Self-citationPizon, T., Rajzer, M., Wojciechowska, W., Wach-Pizoń, M., Dróżdż, T., Wróbel, K., Gruszka, K., Rojek, M., Kameczura, T., Jurczyszyn, A. J., et al. (2018) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320318810022 · Cited by 15
MicroRNA-148a regulates low-density lipoprotein metabolism by repressing the (pro)renin receptor
Wang, N., He, L., Lin, H., Tan, L., Sun, Y., Zhang, X., Danser, A. H. J., Lu, H. S., He, Y., & Lu, X. (2020) · PLoS ONE · doi:10.1371/journal.pone.0225356 · Cited by 13
Self-citationVacuolar H+‐ATPase in Diabetes, Hypertension, and Atherosclerosis
Wang, N., Ren, L., & Danser, A. H. J. (2024) · Microcirculation · doi:10.1111/micc.12855 · Cited by 11
Self-citationThe role of (pro)renin receptor and its soluble form in cardiovascular diseases
Wang, B., Jie, H., Wang, S., Dong, B., & Zou, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1086603 · Cited by 9
Kwakernaak, A. J., Roksnoer, L. C. W., Heerspink, H. J. L., Garrelds, I. M., Lochorn, G. A., Andres, J. H. V. E., Klijn, M. A., Kobori, H., Danser, A. H. J., Laverman, G. D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169258 · Cited by 9
Self-citationImmunohistochemistry for (Pro)renin Receptor in Humans
Morimoto, S., Morishima, N., Watanabe, D., Kato, Y., Shibata, N., & Ichihara, A. (2021) · International Journal of Endocrinology · doi:10.1155/2021/8828610 · Cited by 9
Renin-Angiotensin-Aldosterone System
Speth, R. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00160-2 · Cited by 8
Hsieh, Y., Wu, P., Lin, Y.-T., Huang, Y., Hou, M., Lee, K., & Lin, H. (2022) · The FASEB Journal · doi:10.1096/fj.202200594r · Cited by 8
Principle role of the (pro)renin receptor system in cardiovascular and metabolic diseases: An update
Zhu, M., Yi, X., Song, S., Yang, H., Yu, J., & Xu, C. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111417 · Cited by 7
Ye, D., Yang, X., Ren, L., Lu, H. S., Sun, Y., Lin, H., Tan, L., Wang, N., Nguyen, G., Bader, M., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.725203 · Cited by 6
Self-citationSoluble (pro)renin receptor as a novel laboratory biomarker of atherosclerosis
Liu, C., Song, S., Yi, X., Yang, H., Xiong, J., Wang, M., Tan, W., Zhu, M., Zheng, L., Yu, J., et al. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024150 · Cited by 6
Prorenin periconceptionally and in pregnancy: Does it have a physiological role?
Wiegel, R. E., von Versen‐Höynck, F., Steegers‐Theunissen, R. P. M., Steegers, E. A. P., & Danser, A. H. J. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111281 · Cited by 6
Self-citation(Pro)renin Receptor and LDL Clearance
Strong, A., & Musunuru, K. (2016) · Circulation Research · doi:10.1161/circresaha.115.308068 · Cited by 6
Crosstalk between renin and arachidonic acid (and its metabolites)
Das, U. N., Hacımüftüoğlu, A., Akpınar, E., Gül, M., & El‐Aty, A. M. A. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02463-3 · Cited by 5
Do prorenin-synthesizing cells release active, ‘open’ prorenin?
Martini, A. G., Krop, M., Saleh, L., Garrelds, I. M., & Danser, A. H. J. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001174 · Cited by 5
Self-citationDu, J., Yan, L., Zhang, W. Y., Xu, H., & Zhu, Q. (2020) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2020.03.99 · Cited by 4
The Role of (Pro)Renin Receptor in the Metabolic Syndrome
Yiannikouris, F. B., & Nichols, K. (2022) · Current Hypertension Reviews · doi:10.2174/1573402118666220216104816 · Cited by 4
Psychiatric symptoms following vasectomy.
Wig, N. N., Singh, S. R., Sahasi, G., & Isaac, P. (1970) · PubMed · Cited by 4
Yang, Y., Huang, W., Yang, J., Yang, J. M., Liu, X., Yang, C., & Zeng, P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.151 · Cited by 3
Circulation Research “In This Issue” Anthology
Williams, R. R. E., & Editors, T. (2017) · Circulation Research · doi:10.1161/res.0000000000000152 · Cited by 2
Wang, N., Lu, X., & Danser, A. H. J. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.31518 · Cited by 1
Self-citationSun, K., Zhang, W., Liu, W., Bai, C., Jiang, Y., Zhang, Y., & Song, W. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0038 · Cited by 1
Dong, Y., Zhang, W., Liu, W., Bai, C., Zhang, Y., Jiang, Y., & Song, W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.03.588014 · Cited by 1
Kochuieva, M. M., Psarova, V., Кириченко, Н. М., Ruban, L., Kochuiev, G., & Shalimova, A. (2019) · Family Medicine · doi:10.30841/2307-5112.2.2019.175181
Khodashahi, R., Ferns, G. A., Aliakbarian, M., & Arjmand, M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673345528241101092336
Kourieh, L., & Arab, O. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1008850
Abuloghod, L. (2023) · eScholarship@McGill (McGill) · doi:10.82308/15818
Kim, H. K., & Han, J. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0332
Strong, A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312656 · Cited by 6
Metadata
- Authors
- Lu, X., Meima, M. E., Nelson, J. K., Sorrentino, V., Loregger, A., Scheij, S., Dekkers, D. H. W., Mulder, M. T., Demmers, J. A. A., M-Dallinga-Thie, G., Zelcer, N., & Danser, A. H. J.
- Affiliations
- Shenzhen University (CN)
- From the Astra Zeneca-Shenzhen University Joint Institute of Nephrology, Shenzhen University Medical Center, Shenzhen University, Shenzhen, China (X.L.); Division of Pharmacology and Vascular Medicine, Department of Internal Medicine (X.L., M.E.M., M.T.M., A.H.J.D.) and Proteomics Center (D.H.W.D., J.A.A.D.), Erasmus Medical Center, Rotterdam, The Netherlands; and Department of Medical Biochemistry (X.L., J.K.N., V.S., A.L., S.S., N.Z.) and Laboratory of Experimental Vascular Medicine (G.M.D-.T.),...
- ORCID
- Venue
- Circulation Research
- Published
- 2016-01-22
- Volume
- 118
- Issue
- 2
- Pages
- 222-229
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2172668126
- Cited by
- 48
- References
- 48
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 9 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 5
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Circulation Research (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- National University of Singapore (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- National Natural Science Foundation of China
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Top Institute Pharma
- FP7 Ideas: European Research Council (617376)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- prorenin receptor, low density lipoprotein metabolism, LDL receptor, SORT1, protein-protein interaction, hepatocytes, LDL uptake, post-transcriptional regulation, protein degradation, lysosomal degradation, bafilomycin A1, vacuolar H+-ATPase
- MeSH terms
- Prorenin Receptor, Sortilin, Animals, Cricetulus, Endocytosis, Humans, Lipoproteins, LDL, Protein Processing, Post-Translational, Receptors, Cell Surface, Receptors, LDL, Transfection, CHO Cells, Hepatocytes, Vacuolar Proton-Translocating ATPases, Adaptor Proteins, Vesicular Transport, RNA Interference, Proteomics, Chromatin Immunoprecipitation, Hep G2 Cells, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review